Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.73 |
| ▸ | GSK3B | P49841 | 10/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953627 | 0.95 | GSK3B (0.70) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12954192 | 0.91 | CDK2 (0.70) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13122668 | 0.88 | CDK2 (0.77) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12954189 | 0.88 | GSK3B (0.64) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13305586 | 0.87 | CDK2 (0.81) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953622 | 0.86 | GSK3B (0.65) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953533 | 0.86 | GSK3B (0.65) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953540 | 0.86 | CDK2 (0.68) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953601 | 0.85 | CDK2 (0.81) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953026 | 0.85 | CDK2 (0.81) | CDK2GSK3BCCNE1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130570-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885GSK3B 695/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.